According to FutureWise analysis the market for triple-negative breast cancer treatment in 2023 is US$ 0.63 billion, and is expected to reach US$ 0.86 billion by 2031 at a CAGR of 3.9%.
Breast cancer that is classified as triple-negative lacks either estrogen or progesterone receptors (ER or PR), as well as making either too little or too much of the HER2 protein. (All three tests yield "negative" results for the cells.) These malignancies tend to affect women under the age of 40 who are Black or carry the BRCA1 mutation more frequently. Triple-negative breast cancer is considered aggressive cancer because it grows quickly and is more likely to have spread when discovered. TNBC is likely to reoccur after treatment than other types of breast cancer. The majority of triple-negative tumours are basal-like molecular subtypes of breast cancer, but the terms are not entirely synonymous. Around 10-15% of all breast tumours are triple-negative breast cancers (TNBC).
HER2 positive/oestrogen receptor (ER) negative subtype and the basal-like subtype are two hormone receptor-negative subtypes of breast cancer that have been identified through gene expression studies. The luminal subtypes, which typically express hormone receptor-related genes, are another major subtype of breast cancer. The prognosis of the subtypes varies, with the two-hormone receptor-negative categories typically having worse results than the luminal divisions. The prognostic environment for breast cancer may alter, though, as a result of advancements in chemotherapy, endocrine therapy, and HER2-targeted therapy. Chemotherapy is the backbone of treatment for triple-negative breast cancer because it is resistant to hormonal treatments like tamoxifen and aromatase inhibitors as well as HER2-targeted medications like trastuzumab. The interest in this group of patients has grown as a result of the absence of targeted medicines.
According to the research study conducted by FutureWise research analysts, the Triple Negative Breast Cancer Treatment Market is anticipated to attain substantial growth by the end of the forecast period.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Triple-Negative-Breast/249
Triple Negative Breast Cancer Treatment Market Segmentation:
By Drug Type
- Doxorubicin
- Cyclophosphamide
- Paclitaxel
- Docetaxel
- Cisplatin/Carboplatin
- Others
By Distribution Channel
- Hospital Pharmacies
- Specialty Cancer Clinics
By Region
- Europe
- North America
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Triple Negative Breast Cancer Treatment Market:
- AstraZeneca PLC.
- Pfizer, Inc.
- F. Hoffman - La Roche Ltd.
- Bristol-Myers Squibb Company
- Novartis AG
- Mylan N.V.
- Eli Lilly and Company
- Celgene Corporation
- Sanofi S.A.
- Johnson Johnson Services, Inc
Ask For Discount: https://www.futurewiseresearch.com/contact.aspx?rpt=249%20type=discount
**Objectives of this Study: **
- To provide a comprehensive analysis of the Triple Negative Breast Cancer Treatment Market By Drug Type, By Distribution Channel, and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
FutureWise Research
Contact Person: Vinay Thaploo.
Email: sales@futurewiseresearch.com
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com
